Cargando…

Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial

INTRODUCTION: Upfront surgeries are not beneficial to most patients with pancreatic cancer. Therefore, more emphasis has been placed chemoradiotherapy in locally advanced pancreatic cancer recently. Gemcitabine-based regimens or FOLFIRINOX (a chemotherapy regimen including leucovorin, 5-FU, irinotec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xiaofei, Ju, Xiaoping, Cao, Fei, Fang, Fang, Qing, Shuiwang, Shen, Yuxin, Jia, Zhen, Cao, Yangsen, Zhang, Huojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168617/ https://www.ncbi.nlm.nih.gov/pubmed/27909037 http://dx.doi.org/10.1136/bmjopen-2016-013220

Ejemplares similares

Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2017)

Stereotactic Radiation Therapy (SRT) for Brain Metastases of Multiple Primary Tumors: A Single Institution Retrospective Analysis
por: Gu, Lei, et al.
Publicado: (2019)

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases
por: Shen, Yuxin, et al.
Publicado: (2021)

Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer
por: Zhao, Xianzhi, et al.
Publicado: (2018)

Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial
por: Zhu, Xiaofei, et al.
Publicado: (2022)

Optimization of dose distributions of target volumes and organs at risk during stereotactic body radiation therapy for pancreatic cancer with dose-limiting auto-shells
por: Cao, Yangsen, et al.
Publicado: (2018)

Biologically effective doses of 60–70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial
por: Ye, Yusheng, et al.
Publicado: (2022)

Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration
por: Cao, Yangsen, et al.
Publicado: (2023)

Phase I study of dose‐escalated stereotactic body radiation therapy for locally advanced pancreatic head cancers: Initial clinical results
por: Qing, Shuiwang, et al.
Publicado: (2021)

Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study
por: Jia, Zhen, et al.
Publicado: (2023)

Correction: Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study
por: Jia, Zhen, et al.
Publicado: (2023)

Combination of Pre-Treatment DWI-Signal Intensity and S-1 Treatment: A Predictor of Survival in Patients with Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy and Sequential S-1
por: Zhang, Yu, et al.
Publicado: (2018)

Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)
por: Gao, Suizhi, et al.
Publicado: (2019)

Proteomic Analysis of Radiation-Induced Acute Liver Damage in a Rabbit Model
por: Jiang, Lingong, et al.
Publicado: (2019)

Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China
por: Zhao, Xianzhi, et al.
Publicado: (2021)

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China
por: Xu, Chenyang, et al.
Publicado: (2022)

Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China
por: Zhao, Xianzhi, et al.
Publicado: (2020)

Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy
por: Zhu, Xiaofei, et al.
Publicado: (2021)

Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy
por: Ren, Shengnan, et al.
Publicado: (2020)

Factors associated with de novo metastatic disease in invasive breast cancer: comparison of artificial neural network and logistic regression models
por: Qiu, Chunyan, et al.
Publicado: (2019)

Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy
por: Zhang, Yu, et al.
Publicado: (2018)

Retraction Note: Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy
por: Zhang, Yu, et al.
Publicado: (2018)

Deep Learning–Based Fluence Map Prediction for Pancreas Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost
por: Wang, Wentao, et al.
Publicado: (2021)

Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients
por: Liu, Xiaojie, et al.
Publicado: (2017)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy—rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial
por: Begum, Housne, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost in Patients With Spinal Metastases
por: Pontoriero, Antonio, et al.
Publicado: (2020)

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer
por: Xu, Bichun, et al.
Publicado: (2023)

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018)

Rationale of the PAPAartis trial
por: Misfeld, Martin, et al.
Publicado: (2023)

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
por: Paydar, Ima, et al.
Publicado: (2016)

Rationale for sequential extracorporeal therapy (SET) in sepsis
por: Ronco, Claudio, et al.
Publicado: (2023)

Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery
por: Kim, Mi-Sook, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1vtssndt60sb3ldgdstvhciun6